Key Highlights

  • Wide Open Agriculture plans to close its German Facility by mid-2027 and move towards outsourced Manufacturing in Asia.
  • The initial contract-manufacturing target is approximately 500 to 1,000 tonnes a year of lupin protein isolate.
  • The whole-of-seed model aims to commercialise protein, lupin oil, fibre and other co-products.
  • Early lupin-oil sales have been secured, although volumes and Revenue were not disclosed.

Wide Open Agriculture is a Western Australian ingredients company built on a regenerative-agriculture narrative, turning lupins — a high-protein legume that fixes nitrogen and enriches soil — into products for food, beverages, nutraceuticals and, increasingly, cosmetics. Having divested its former Dirty Clean Food retail Business in 2024, it is now a pure-play lupin-ingredients operation.

Company Overview

Wide Open Agriculture is a Western Australian ingredients company built on a regenerative-agriculture narrative, turning lupins — a high-protein legume that fixes nitrogen and enriches soil — into products for food, beverages, nutraceuticals and, increasingly, cosmetics. Having divested its former Dirty Clean Food retail business in 2024, it is now a pure-play lupin-ingredients operation.

Latest Update

The most concrete recent development came on 2 July 2026, when Wide Open Agriculture announced a strategic pivot: it is winding down its German lupin-protein facility, with full closure targeted by mid-2027, and moving to outsourced contract manufacturing, with Asia the preferred location. The plan is a staged scale-up, initially targeting 500 to 1,000 tonnes a year of lupin protein isolate, alongside commercialising co-products including lupin oil and fibre. Early lupin-oil sales have been secured, though volumes and revenue were not disclosed.

Operations and Strategic Direction

The company's whole-of-seed strategy aims to extract multiple products from a single input. Its flagship is Buntine Protein, a lupin protein isolate made using a de-bittering process licensed from Curtin University and targeted at protein shakes, baked goods and plant-based dairy; lupin oil is the higher-value co-product aimed at skincare; and fibre and other fractions round out the portfolio. A new chief executive with an ingredients-industry background started in April 2026.

Financial and Market Snapshot

The financials are those of a distressed micro-cap. The shares traded around one cent in late July 2026, near 52-week lows, for a Market Capitalisation of about AUD 5.9 million — roughly half its level six months earlier. The most recent cash figure that could be verified was around AUD 2.5 million, but that dated back to early 2025 and is likely materially lower now given ongoing burn and restructuring, so the current balance is uncertain and should be confirmed against the latest quarterly.

Broader Context

The next update should clarify whether current plans are translating into measurable outcomes. Operational progress should ultimately be assessed through Cash Flow , delivery and repeatable results. The latest update provides a useful baseline for assessing the next reporting period. Margins will help show whether current revenue trends are creating sustainable financial progress. Cash conversion offers another practical measure of the quality of reported Earnings . Management execution will remain central as the company advances its stated strategic priorities.

What May Be Watched Next

The near-term signals are the next Quarterly Report , which should clarify the cash position and any lupin-oil and protein sales run-rate; a binding lupin-oil or skincare offtake agreement and any quantified actives study; the signing of an Asian contract-manufacturing partner and first isolate volumes under the new model; China commercialisation milestones; and, given the cash needs, a likely funding event whose terms will be a key dilution signal.

Key Risks

The risks are severe. As a nano-cap with a shrinking cash balance and a restructuring under way, Wide Open Agriculture faces going-concern and funding risk and is highly likely to need further dilutive raises. The shares have been heavily destroyed, near lows and with the Market Value halved in six months, and the core products remain pre-commercial: the lupin-oil skincare opportunity and the contract-manufacturing scale-up are largely unproven, with early sales undisclosed and immaterial.